Pre-analytical in-vitro stability of [-2]proPSA in blood and serum

Clinical Biochemistry

Volumn 43, Issue 10-11, 2010, Pages 926-928

  Semjonow, Axel ^a   Köpke, Thomas ^a   Eltze, Elke ^b   Pepping Schefers, Beate ^a   Bürgel, Hilla ^a   Darte, Claude ^c  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c BECKMAN COULTER INC   (United States)

Author keywords

2 proPSA; Biological markers blood; Humans; In vitro stability; Prostate cancer; Prostate specific antigen blood

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALYZER; ANTIGEN DETECTION; ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING TIME; BLOOD SAMPLING; BLOOD STORAGE; CENTRIFUGATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FREEZE THAWING; HUMAN; IMMUNOASSAY; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROTEIN STABILITY; ROOM TEMPERATURE; TEMPERATURE DEPENDENCE; BLOOD; PREDICTIVE VALUE; REFERENCE VALUE; STATISTICAL MODEL;

BLOOD PRESERVATION; BLOOD SPECIMEN COLLECTION; HUMANS; IMMUNOASSAY; LINEAR MODELS; MALE; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; REFERENCE VALUES;

EID: 77953717799     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.04.062     Document Type: Article

References (18)

1. Peter J., Unverzagt C., Krogh T.N., Vorm O., Hoesel W. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 2001, 61:957-962.
2. Mikolajczyk S.D., Marker K.M., Millar L.S., Kumar A., Saedi M.S., Payne J.K., et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001, 61:6958-6963.
3. Mikolajczyk S.D., Millar L.S., Wang T.J., Rittenhouse H.G., Marks L.S., Song W., et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 2000, 60:756-759.
4. Catalona W.J., Bartsch G., Rittenhouse H.G., Evans C.L., Linton H.J., Amirkhan A., et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4ng/ml. J Urol 2003, 170:2181-2185.
5. Mikolajczyk S.D., Catalona W.J., Evans C.L., Linton H.J., Millar L.S., Marker K.M., et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 2004, 50:1017-1025.
6. Naya Y., Fritsche H.A., Bhadkamkar V.A., Mikolajczyk S.D., Rittenhouse H.G., Babaian R.J. Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer. Urol Oncol 2005, 23:16-21.
7. Sokoll L., Wang Y., Feng Z., Kagan J., Partin A.W., Sanda M.G., et al. [-2]Proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol 2008, 180:539-543.
8. Stephan C., Kahrs A.M., Cammann H., Lein M., Schrader M., Deger S., et al. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 2009, 69:198-207.
9. Lein M., Semjonow A., Graefen M., Kwiatkowski M., Abramjuk C., Stephan C., et al. A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. J Urol 2005, 174:2150-2153.
10. Woodrum D., French C., Shamel L.B. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology 1996, 48:33-39.
11. Sweep F.C., Fritsche H.A., Gion M., Klee G.G., Schmitt M. Considerations on development, validation, application, and quality control of immuno(metric) biomarker assays in clinical cancer research: an EORTC-NCI working group report. Int J Oncol 2003, 23:1715-1726.
12. van den Bergh R.C., Vasarainen H., van der Poel H.G., Vis-Maters J.J., Rietbergen J.B., Pickles T., et al. Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: active surveillance' study. BJU Int 2009, 105:956-962.
13. Lundwall A., Lilja H. Molecular cloning of human prostate specific antigen with cDNA. FEBS Lett 1987, 214:317-322.
14. Kumar A., Mikolajczyk S.D., Goel A.S., Millar L.S., Saedi M.S. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 1997, 57:3111-3114.
15. Takayama T.K., Fujikawa K., Davie E.W. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J Biol Chem 1997, 272:21582-21588.
16. Lövgren J., Rajakoski K., Karp M., Lundwall A., Lilja H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 1997, 238:549-555.
17. Darson M.F., Pacelli A., Roche P., Rittenhouse H.G., Wolfert R.L., Young C.Y., et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 1997, 49:857-862.
18. Balk S.P., Ko Y.J., Bubley G.J. Biology of prostate-specific antigen. J Clin Oncol 2003, 21:383-391.